Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Long-Term Investments: 2021-2025

Historic Long-Term Investments for C4 Therapeutics (CCCC) over the last 5 years, with Sep 2025 value amounting to $7.9 million.

  • C4 Therapeutics' Long-Term Investments fell 72.62% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year decrease of 72.62%. This contributed to the annual value of $22.4 million for FY2024, which is 20.17% down from last year.
  • As of Q3 2025, C4 Therapeutics' Long-Term Investments stood at $7.9 million, which was down 6.46% from $8.4 million recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' Long-Term Investments peaked at $142.2 million during Q4 2021, and registered a low of $7.9 million during Q3 2025.
  • Its 3-year average for Long-Term Investments is $24.7 million, with a median of $28.0 million in 2023.
  • In the last 5 years, C4 Therapeutics' Long-Term Investments spiked by 301.53% in 2022 and then slumped by 78.44% in 2023.
  • Over the past 5 years, C4 Therapeutics' Long-Term Investments (Quarterly) stood at $142.2 million in 2021, then tumbled by 57.13% to $61.0 million in 2022, then slumped by 54.06% to $28.0 million in 2023, then dropped by 20.17% to $22.4 million in 2024, then slumped by 72.62% to $7.9 million in 2025.
  • Its last three reported values are $7.9 million in Q3 2025, $8.4 million for Q2 2025, and $19.6 million during Q1 2025.